Dual potency anti-HER2/neu and anti-EGFR anthracycline immunoconjugates in chemotherapeutic-resistant mammary carcinoma combined with cyclosporin A and verapamil P-glycoprotein inhibition.
about
Dexamethasone-(C21-phosphoramide)-[anti-EGFR]: molecular design, synthetic organic chemistry reactions, and antineoplastic cytotoxic potency against pulmonary adenocarcinoma (A549)Gemcitabine-(5'-phosphoramidate)-[anti-IGF-1R]: molecular design, synthetic organic chemistry reactions, and antineoplastic cytotoxic potency in populations of pulmonary adenocarcinoma (A549)Synthesis of a covalent epirubicin-(C(3)-amide)-anti-HER2/neu immunochemotherapeutic utilizing a UV-photoactivated anthracycline intermediateSimultaneous Dual Selective Targeted Delivery of Two Covalent Gemcitabine Immunochemotherapeutics and Complementary Anti-Neoplastic Potency of [Se]-MethylselenocysteineAnti-Neoplastic Cytotoxicity of Gemcitabine-(C4-amide)-[anti-EGFR] in Dual-combination with Epirubicin-(C3-amide)-[anti-HER2/neu] against Chemotherapeutic-Resistant Mammary Adenocarcinoma (SKBr-3) and the Complementary Effect of Mebendazole.Synthesis of Gemcitabine-(C4-amide)-[anti-HER2/neu] Utilizing a UV-Photoactivated Gemcitabine Intermediate: Cytotoxic Anti-Neoplastic Activity against Chemotherapeutic-Resistant Mammary Adenocarcinoma SKBr-3.Influence of Alternative Tubulin Inhibitors on the Potency of a Epirubicin-Immunochemotherapeutic Synthesized with an Ultra Violet Light-Activated Intermediate: Influence of incorporating an internal/integral disulfide bond structure and AlternativeEpirubicin-[Anti-HER2/neu] Synthesized with an Epirubicin-(C13-imino)-EMCS Analog: Anti-Neoplastic Activity against Chemotherapeutic-Resistant SKBr-3 Mammary Carcinoma in Combination with Organic Selenium.Fludarabine- (C2-methylhydroxyphosphoramide)- [anti-IGF-1R]: Synthesis and Selectively "Targeted"Anti-Neoplastic Cytotoxicity against Pulmonary Adenocarcinoma (A549)Design and In Vivo Characterization of Immunoconjugates Targeting HIV gp160.Gemcitabine-(C4-amide)-[anti-HER2/neu] Anti-Neoplastic Cytotoxicity in Dual Combination with Mebendazole against Chemotherapeutic-Resistant Mammary Adenocarcinoma.Anti-Neoplastic Cytotoxicity of Gemcitabine-(C4-amide)-[anti-HER2/neu] in Combination with Griseofulvin against Chemotherapeutic-Resistant Mammary Adenocarcinoma (SKBr-3).Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impact
P2860
Q28829762-5095150D-133E-4B16-930B-1847FE7FF000Q33578254-D44F5DB0-BCDE-4AD7-B056-A63AB2EA4322Q35180943-E77B54AF-C96A-402E-97ED-90E40E56A7BBQ35222776-918FC3CD-32FE-42D1-A8A2-B43643C65908Q35237773-5CA9E092-93DF-4CBE-A720-94B854F067FBQ35892041-8B29E139-5869-4AF2-85D7-C768FAF918FDQ35892045-FED3DABB-716F-48EE-AF45-A370F8C123C6Q35896698-29D6F433-FB45-4220-8866-C93AA54E6E35Q36311218-D1D3B45C-A276-465C-92EE-1322BD06AB25Q37593171-95257EA7-6C4F-4EF4-A42B-6263CF3859CBQ40649082-BA867096-A2E7-4B03-8946-7C0253AEE270Q40678981-C9E12D64-5376-43B0-B150-9E4D35B01835Q57579477-BAECC496-9056-4710-ABAE-F9463AC3C34C
P2860
Dual potency anti-HER2/neu and anti-EGFR anthracycline immunoconjugates in chemotherapeutic-resistant mammary carcinoma combined with cyclosporin A and verapamil P-glycoprotein inhibition.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Dual potency anti-HER2/neu and ...... mil P-glycoprotein inhibition.
@en
Dual potency anti-HER2/neu and ...... mil P-glycoprotein inhibition.
@nl
type
label
Dual potency anti-HER2/neu and ...... mil P-glycoprotein inhibition.
@en
Dual potency anti-HER2/neu and ...... mil P-glycoprotein inhibition.
@nl
prefLabel
Dual potency anti-HER2/neu and ...... mil P-glycoprotein inhibition.
@en
Dual potency anti-HER2/neu and ...... mil P-glycoprotein inhibition.
@nl
P2093
P2860
P1476
Dual potency anti-HER2/neu and ...... mil P-glycoprotein inhibition.
@en
P2093
John G Bailey
Matt K Ross
P2860
P304
P356
10.1080/10611860903012802
P577
2009-07-01T00:00:00Z